280 related articles for article (PubMed ID: 16291708)
21. Can neurotrophic factors prevent or reverse motoneuron injury in amyotrophic lateral sclerosis?
Appel SH; Smith RG
Exp Neurol; 1993 Nov; 124(1):100-2. PubMed ID: 8282067
[No Abstract] [Full Text] [Related]
22. Treatment of amyotrophic lateral sclerosis.
Eisen A; Weber M
Drugs Aging; 1999 Mar; 14(3):173-96. PubMed ID: 10220104
[TBL] [Abstract][Full Text] [Related]
23. [Amyotrophic lateral sclerosis. Fatal diagnosis -- how still can be helped?].
Stiefelhagen P
MMW Fortschr Med; 2004 Nov; 146(47):16. PubMed ID: 15624649
[No Abstract] [Full Text] [Related]
24. [Amyotrophic lateral sclerosis].
Martí-Fàbregas J; Pradas J
Neurologia; 1996 Mar; 11(3):99-108. PubMed ID: 8695148
[TBL] [Abstract][Full Text] [Related]
25. [Clinical significance of treatment with riluzole].
Meininger V; Lacomblez L; Bensimon G
Rev Neurol (Paris); 1997 Oct; 153(10):539-40. PubMed ID: 9684016
[No Abstract] [Full Text] [Related]
26. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
de Carvalho M; Swash M
Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic trials in ALS.
Bradley W
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):6-7. PubMed ID: 12745610
[No Abstract] [Full Text] [Related]
28. What is next in ALS clinical trials?
Sorenson EJ
Neurology; 2007 Aug; 69(8):719-20. PubMed ID: 17709702
[No Abstract] [Full Text] [Related]
29. New approaches to therapy of amyotrophic lateral sclerosis.
Miller RG
West J Med; 1998 Apr; 168(4):262-3. PubMed ID: 9584665
[No Abstract] [Full Text] [Related]
30. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective therapy in Parkinson disease.
Chen S; Le W
Am J Ther; 2006; 13(5):445-57. PubMed ID: 16988541
[TBL] [Abstract][Full Text] [Related]
32. Riluzole for ALS: what is the evidence?
Miller R
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):135. PubMed ID: 13129798
[No Abstract] [Full Text] [Related]
33. [Etiological drug therapy for amyotrophic lateral sclerosis].
Cintas P
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
[TBL] [Abstract][Full Text] [Related]
34. [Riluzole for everybody or for nobody].
Martí-Fàbregas J
Neurologia; 1996 Jan; 11(1):44-5. PubMed ID: 8714179
[No Abstract] [Full Text] [Related]
35. New ideas for therapy in ALS: critical considerations.
Beghi E; Bendotti C; Mennini T
Amyotroph Lateral Scler; 2006 Jun; 7(2):126-7; discussion 127. PubMed ID: 16753979
[No Abstract] [Full Text] [Related]
36. Therapeutic developments in the treatment of amyotrophic lateral sclerosis.
Jackson M; Lladó J; Rothstein JD
Expert Opin Investig Drugs; 2002 Oct; 11(10):1343-64. PubMed ID: 12387699
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic trials in amyotrophic lateral sclerosis.
Olarte MR
Adv Neurol; 1982; 36():555-7. PubMed ID: 6758531
[No Abstract] [Full Text] [Related]
38. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
Dib M
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
[TBL] [Abstract][Full Text] [Related]
39. [Epidemiology and treatment of amyotrophic lateral sclerosis].
Camu W
Soins; 2008 Jun; (726):40-3. PubMed ID: 18697338
[No Abstract] [Full Text] [Related]
40. Future national study group in ALS.
Ringel SP
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():135-6. PubMed ID: 15512897
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
